Clinical Trial Update: A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing asunaprevir plus daclatasvir versus telaprevir in Japanese patients with hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• Daclatasvir (daclatasvir)
• Telaprevir (telaprevir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED